68Ga-NY104

N/A

Report date: 2025/09/09 13:36:34

NME

Base Information

Drug Name68Ga-NY104

Drug Alias Name68Ga (2-5mCi) labelled NY10468Ga-labeled NY10468Ga-NYM005 PET/CT68Ga-NY104 PET/CTGallium-68 NYM 005 +[9]

ClassificationSmall molecules > Heterocyclic drugsRadiation-emitting products > Radioactive diagnostic agentRadiation-emitting products > Nuclides > Gallium > 68Ga +[4]

Mechanisms of ActionPositron-emission tomography enhancersCarbonic anhydrase IX inhibitors

TargetsCarbonic anhydrase IX

Therapy Area/IndicationsCarcinoma, Renal Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesMainland China

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaPhase 2 Clinical

Originator CompaniesWuxi Nuoyu Pharmaceutical Technology Co Ltd

China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesNorroy Bioscience Co Ltd Wuxi Nuoyu Pharmaceutical Technology Co Ltd

Inactive CompaniesN/A

Active IndicationsCarcinoma, Renal Cell

Inactive IndicationsN/A

Other Information

ATC CodeN/A